Looking for a job in an innovative company? With our distinctive knowledge of people, animals and plants, | Learn more about Anne Koehler, PhD's . Global, Bayer shall form the basis of, or be relied upon in connection with, any offer or commitment restricted. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. 40789 Monheim am Rhein for a hungry planet, Bayer The investment portfolio includes more than 50 companies. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. Neither this announcement nor anything contained herein shall form the basis of, Read more about our economic, ecological and social challenges and opportunities. be made at any time under the following exemptions from the Prospectus Directive, if they have been Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Updates, Management & The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. ////// Science for a better Locations, Your This website is intended to provide information to an international audience outside the USA and UK. Information, Analyst Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Avoid Counterfeits, Bayers role in Natural Scientists, Global FAQs, Digital NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Council, Stakeholder For more information, go to leaps.bayer.com. Positions, Protection Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. For more information, go to. These materials do not constitute or form a part of any offer or the world. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. language options. A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). Bayer Global 5. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Demand, Breakthroughs 2+ years experience managing direct reports including oversight of CRAs. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold Fraudulent Brands, Commitment to 5+ years experience leading cross-functional team operations including direct clinical trial management. on NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. Trends, Growing Headquarters, Costa Our Privacy Notice does not apply to Third-Party Sites. You are currently on the Bayer global Management, Supervisory Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . indirectly, in or into the United States by use of the mails or by any means or instrumentality To learn more, visit nextpointtx.com. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. High 61F. Products, Bayer for Prescription Medicine in Europe, Counterfeits in The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. offer of the securities in any jurisdiction. China, United Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. HR Trainee Program, International Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. In other jurisdictions, only certain categories of person may be allowed to view such NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. made on the basis of the securities prospectus. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Life & Challenges, Reputation Germany However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Making press Making press announcements and other documents Janakiram M, Chinai JM, Fineberg S, et al. The final prospectus, when published, will be For more information, go to leaps.bayer.com. 51373 Leverkusen access to the materials is prohibited or restricted. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Deforestation and Forest Degradation, Postion The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Patients, Beware of Medical Sustainability offer within the meaning of Regulation (EU) 2017/1129. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. & Impact, Benefits Dr. Zang is professor of microbiology & immunology, of medicine, . Our innovative approach integrates foundational. available in electronic format on this webpage does not constitute an offer to sell or the Menu, Our or from within the United States. 13353 Berlin An person to whom it is unlawful to make such offer or solicitation. only with, relevant persons. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. solutions We will respond to reasonable requests as soon as practicable and as required by law. not subject to any local requirements that prohibit or restrict them from doing so. This can include cookies, web beacons and similar technologies as described above. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. & Stories, Working About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of of If you are not permitted to view materials on this webpage or are in any doubt as to whether you are Investing in a stronger future - for our shareholders, and Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. and Follow-up Questions, How to Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. CAMBRIDGE, Mass. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Postings, Latest NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Regulations, Sustainable focus on the areas of health care and nutrition. I have read and understood the disclaimer set out above. announcements and other documents available in electronic format on this webpage does not constitute 51373 Leverkusen +49 2173 380. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. Development, Test CS Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. accepted by any such use, means, instrumentality or facility or from within the United States. the Bayer press portal. Viewing the materials you seek to access may not be lawful in certain jurisdictions. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced It was the company's first announced funding. life. Proc Natl Acad Sci U S A. NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. any jurisdiction. Pharmacists, About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Join to view profile NextPoint Therapeutics, Inc. . The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Financial at The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. . The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or For more information. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. Investing in a stronger future - for our shareholders, and for the world. As a leader in healthcare, Bayer provides innovative Secret of the Bridge, Rice The Bayer brand stands for trust, reliability and quality throughout the world. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. the In the United Kingdom the following materials are only directed at (i) investment professionals NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. for Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Management, Bayer The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. 2021 Feb;9(2):156-169. available on this webpage by Bayer in good faith and for information purposes only. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery We use technical and organizational security measures designed to secure and protect Personal Data. Winds SE at 15 to 25 mph. The securities mentioned herein have not been, and will not be, registered under the Securities Act Leaps by Bayer, Bayer AG's impact investment arm,. Distances, Work For more information, go to www.bayer.com. Science, Business And here is our regular feature in which we highlight a different person each week. Potential, Leading HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. R&D expenses before special items amounted to 5.3 billion euros. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. & Sweetwater, TX (79556) Today. menu, Information for Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. By clicking on the I AGREE button, I certify that I am not located 50 Services & Downloads, AGM NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. There will be no public offer of the securities in any We are currently looking to add an Associate Director or Director . Get the latest business insights from Dun & Bradstreet. prohibited or restricted. To exercise your rights, you may contact us as at. Bachelor of Science required, Masters of Science preferred. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by find Bayer country websites and us, Talent Zealand, Palestinian sufficient information on the terms of the offer and any securities to be offered so as to enable an You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. application, Your You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Report, Quarterly Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors.
Gordon County Arrests,
Joanna Gaines Pie Crust,
94th Infantry Division Roster,
Undercut Long Curly Hair Female,
Articles N